Ingredient · Evidence grade D
Pueraria mirifica for menopause: evidence, studies and safety
Last updated · 2 studies summarized
D Short answer: Pueraria mirifica contains strong plant estrogens. Evidence is limited and low quality, and safety concerns have been reported in Japan. None of the products we ranked contains it.
Key facts
| Evidence grade | D D (efficacy) – safety caution |
|---|---|
| Use studied | menopausal symptoms, vaginal dryness |
| Trials | ~8 small studies (Kongkaew 2018 SR: 309 women), few placebo-controlled |
| Participants | 309 |
| What reviews conclude | Kongkaew 2018: high risk of bias, unstandardized material; efficacy inconclusive. |
| The Menopause Society (2023) | Not assessed. |
| Also known as | kwao krua, Pueraria candollei |
Grades: A strong · B moderate · C limited · D none or negative. How we grade.
Every study we reviewed
Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.
-
Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forward.
A review of all Pueraria mirifica studies found they were small, poorly designed and used unstandardized products, so it is unknown whether it works. Its estrogen-like compounds are strong, which raises safety questions.
- Who
- 8 studies, 309 women
- Dose
- various P. mirifica doses
- Duration
- various
- Result
- Symptom scores fell ~50% from baseline, but studies had high risk of bias, undefined active ingredients and no standardization; CRP doubled.
- Funding
- Academic (Thailand). Independent / academic
-
Effect of Pueraria mirifica on vaginal health.
71 Thai postmenopausal women took Pueraria mirifica or placebo for 24 weeks. Vaginal dryness improved and vaginal tissue showed estrogen-like changes – evidence that it acts like a hormone.
- Who
- 71 women (51 PM, 20 placebo)
- Dose
- P. mirifica, 3 doses
- Duration
- 24 weeks
- Result
- Less vaginal dryness; vaginal cells shifted toward an estrogen-stimulated pattern.
- Funding
- Not stated in abstract. Funding not stated
Safety
Contains potent phytoestrogens (miroestrol, deoxymiroestrol). Japan: 209 consumer harm reports 2012–2017 (irregular bleeding, menstrual disorders) – National Consumer Affairs Center; Food Safety Commission warning; MHLW designated-ingredient case review incl. a fatal liver-failure case (causality suspected); 16.2% of users reported estrogen-related AEs in a Japanese survey. Avoid with hormone-sensitive conditions.
Ranked products that contain it
None of the 27 products we ranked lists this ingredient.
FAQ
Does Pueraria mirifica help with menopause symptoms?
Pueraria mirifica contains strong plant estrogens. Evidence is limited and low quality, and safety concerns have been reported in Japan. None of the products we ranked contains it. Our evidence grade is D (efficacy) – safety caution. Kongkaew 2018: high risk of bias, unstandardized material; efficacy inconclusive.
Does The Menopause Society recommend Pueraria mirifica?
Not assessed. The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.
Is Pueraria mirifica safe?
Contains potent phytoestrogens (miroestrol, deoxymiroestrol). Japan: 209 consumer harm reports 2012–2017 (irregular bleeding, menstrual disorders) – National Consumer Affairs Center; Food Safety Commission warning; MHLW designated-ingredient case review incl. a fatal liver-failure case (causality suspected); 16.2% of users reported estrogen-related AEs in a Japanese survey. Avoid with hormone-sensitive conditions. Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.
Sources
- https://www.kokusen.go.jp/news/data/n-20170713_1.html
- https://www.fsc.go.jp/kigai_jyoho/pueraria_mirifica.html
- https://www.cfs.gov.hk/english/programme/programme_rafs/programme_rafs_fci_02_03.html
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9653890/
- The Menopause Society 2023 nonhormone position statement (PDF)
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.